The Xalkori Clinical Trial Package
This article was originally published in Pharmaceutical Approvals Monthly
Because Pfizer had already started its Phase III trials before filing for accelerated approval, FDA was able to piggy-back most of its post-marketing requirements onto ongoing studies.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
The latest drug development news and highlights from our US FDA Performance Tracker.